Curis (CRIS) Misses Q1 EPS by 2c

Curis (NASDAQ: CRIS) reported Q1 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $2.19 million versus the consensus estimate of $2.64 million.

"The first quarter of 2021 saw continued momentum for our pipeline of next generation targeted cancer therapies designed to meaningfully improve and extend patients' lives. We continued to make important progress with CA-4948, our first-in-class, small molecule inhibitor of IRAK4, now in three clinical trials after expanding into one new study earlier this year with the Phase 2 LUCAS IST for patients with lower-risk MDS, as well as expanding our previous Phase 1/2 study in patients with relapsed/refractory (R/R) NHL to include the combination of CA-4948 plus ibrutinib. We were also very pleased to announce that CA-4948 was granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of AML and MDS, highlighting the unique potential of our IRAK4 program," said James Dentzer, President and Chief Executive Officer of Curis. \"We are especially excited about the AML/MDS data published today in the EHA abstract, and we look forward to providing additional data from this study in the oral presentation at EHA next month."

Mr. Dentzer added, "We are also pleased with the continuing dose escalation in our ongoing Phase 1 study of CI-8993, our first-in-class monoclonal anti-VISTA antibody for the treatment of patients with R/R solid tumors and look forward to providing initial data from this study later this year."

For earnings history and earnings-related data on Curis (CRIS) click here.

You May Also Be Interested In

• ATN International (ATNI) Misses Q1 EPS by 46c ; Offers Guidance
• VIST Financial Corp. (VIST) Misses Q1 EPS by 19c
• SLM (SLM) Tops Q1 EPS by 20c; offers guidance